Efectividad de reslizumab en asma grave no controlada (AGNC) eosinofílica con poliposis nasal asociada

  1. Sara Rivera Gómez 1
  2. J.G. Soto Campos 1
  3. A. Del Cuvillo Bernal 2
  4. M.P. Lobato de la Sierra 1
  5. S. García Morales 1
  6. F. Pérez Grimaldi 1
  1. 1 Servicio de Neumología. Hospital Universitario de Jerez de la Frontera, Cádiz.
  2. 2 Servicio de Otorrinolaringología. Hospital Universitario de Jerez de la Frontera, Cádiz.
Journal:
Revista española de patología torácica

ISSN: 1889-7347

Year of publication: 2023

Volume: 35

Issue: 2

Pages: 158-160

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista española de patología torácica

Abstract

In order to better characterize the profile of asthmatic patients who could benefit from monoclonal antibody treatments, the present study evaluated the effectiveness of reslizumab after one year of treatment in patients with severe uncontrolled eosinophilic asthma, distinguishing those with chronic rhinosinusitis. with associated nasal polyposis (RSCcNP). Reslizumab proved to be effective in this series of patients by reducing asthma exacerbations, improving lung function and asthma control, in addition to reducing the size and symptoms caused by nasal polyposis.

Bibliographic References

  • Buhl R, Bel E, Bourdin A et al. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2022 Feb; 10(2): 422-432. doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 8. PMID: 34763123.
  • Domingo C, Sogo A, Prina E et al. Late Breaking asthma. Prevalence, characterization and cost of severe asthma in Spain(BRAVO I).Eur Respir J 2020;Suppl 64, 4639.
  • Melero Moreno C, Quirce S, Huerta A, et al. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. J Asthma. 2019 Aug; 56(8): 861-871. doi: 10.1080/02770903.2018.1499035. Epub 2018 Oct 9. PMID: 30003827.
  • Wang Q, Sun Q, Chen Q et al. Efficacy and Safety of Anti- Interleukin-5 Therapies in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int Arch Allergy Immunol. 2022 Feb 2:1-12. doi: 10.1159/000521859. Epub ahead of print. PMID: 35108711.
  • Bachert C, Han JK, Wagenmann M et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021 Jan; 147(1): 29-36. doi: 10.1016/j.jaci.2020.11.013. Epub 2020 Nov 20. Erratum in: J Allergy Clin Immunol. 2021 May; 147(5): 1981-1982. PMID: 33227318.
  • Gevaert P, Lang-Loidolt D, Lackner A et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006 Nov; 118(5): 1.133-41. doi: 10.1016/j.jaci.2006.05.031. Epub 2006 Sep 26. PMID: 17088140.
  • Weinstein SF, Katial RK, Bardin P et al. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2019 Feb; 7(2): 589-596.e3. doi: 10.1016/j.jaip.2018.08.021. Epub 2018 Sep 5. PMID: 30193936.
  • Nettis E, Brussino L, PatellaV et al.Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy. 2022 May 19;v20(1):v6. doi: 10.1186/s12948-022-00171-2. PMID: 35590407; PMCID: PMC9121619.
  • Boiko NV, Lodochkina OE, Kit MM, et al.Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma. VestnOtorinolaringol. 2021; 86(2): 43-48. doi: 10.17116/otorino20218602143
  • Nsouli S. Reslizumab an interleukin-5 antagonist monoclonal antibody for uncontrolled chronic rhinosinusitis with nasal polyps. Presented at: the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (Virtual Experience). November 13-15, 2020. Abstract P509.
Data source: Dialnet